Table 1.
Clinical characteristics of the RCC patients and controls studied.
| Screening Stage Cohort | Validation Stage Cohort | ||||
|---|---|---|---|---|---|
| Patients N = 16 |
Controls N = 16 |
Patients N = 51 |
Controls N = 32 |
Angiomyolipomas N = 13 |
|
| Age, y | 67.5 (61.25–71) | 68 (59.50–71.25) | 63 (52–69) | 62.5 (51–71.5) | 61 (45–70) |
| Male sex, N (%) | 13 (81.25%) | 13 (81.25%) | 29 (56.86%) | 21 (65.63%) | 1 (7.69%) |
| Urine creatinine, mg/dL | 80.7 (61.7–147.9) | 85.7 (57.1–111.9) | 70.6 (42.7–122.7) | 96.75 (62.6–154.1) | 64 (53.15–109.3) |
| RCC Tumor type, N (%) | |||||
| ccRCC | 16 (100%) | - | 29 (56.86%) | - | - |
| papRCC | - | - | 16 (31.37%) | - | - |
| chrRCC | - | - | 6 (11.77%) | - | - |
| Tumor Stage, N (%) | |||||
| I | 13 (81.25%) | - | 41 (80.39%) | - | - |
| II | 2 (12.5%) | - | 2 (3.92%) | - | - |
| III | 1 (6.25%) | - | 6 (11.77%) | - | - |
| VI | - | - | 2 (3.92%) | - | - |
Continuous variables are presented as median and interquartile range and categorical variables are presented as count and percentage. ccRCC, clear-cell renal cell carcinoma; papRCC, papillary renal cell carcinoma; chrRCC, chromophobe renal cell carcinoma.